Swiss contract manufacturer Lonza is leveraging its expanding US footprint to capture market share as trade tensions threaten the global generic drug supply chain.
The company sees a strategic opening in the United States, where its new facility in California still holds significant free capacity, allowing it to offer domestic production alternatives to clients facing potential import barriers.
The development comes as US President Donald Trump has threatened to impose tariffs of up to 200% on imported generic medicines.
The development comes as US President Donald Trump has threatened to impose tariffs of up to 200% on imported generic medicines.
Such a move would severely impact European producers like Sandoz, which manufactures the majority of its generic drugs in Europe.
Market observers have questioned whether the US can afford such steep duties on essential medication copies, given the reliance on foreign supply chains.
Lonza’s international production network provides a buffer against these geopolitical risks.